Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Lepidico

    MCap

    AUD107m

    Last close

    AUD0.02

    ▲ 0.01 (100.00%)

    Silver Spruce Resources

    MCap

    CAD5m

    Last close

    CAD0.03

    ▲ 0.01 (50.00%)

    OpGen

    MCap

    USD7m

    Last close

    USD0.17

    ▲ 0.04 (30.77%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

Carmat (PAR: ALCAR)

Currency in EUR

Last close As at 25/01/2023

EUR11.24

▲ −0.64 (−5.39%)

Market capitalisation

EUR260m

Carmat is developing a biocompatible, artificial heart to satisfy the lack of donor hearts available for terminal heart failure patients. Management is taking corrective actions with recent quality challenges.

The Aeson artificial heart is being developed as a permanent replacement or destination therapy for chronic biventricular heart failure or acute myocardial infarction patients who do not have access to a human donor heart.

Latest Insights

View More

Healthcare

Carmat: Edison Open House Healthcare 2022

Healthcare

Carmat — Implantation momentum

Healthcare

Carmat – Edison Open House interview

Healthcare

Carmat – executive interview with Stéphane Piat
Visit Website

Sector

Healthcare

Equity Analyst

Pooya Hemami

Pooya Hemami

Analyst

Key Management

  • Pascale d'Arbonneau

    CFO

  • Piet Jansen

    Chief Medical Officer

  • Stéphane Piat

    CEO

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 8.0 (15.3) (33.2)
Relative 0.0 (24.7) (34.5)
52 week high/low €17.3/€8.4

Financials

Carmat announced in November that it has resumed implantations of its Aeson physiologic heart replacement therapy in a commercial setting, and it expects to continue resuming implant sales in Europe at a gradual pace as it replenishes inventory. The company had implemented controls to improve Aeson quality and safety, in response to defects identified in two components that affected some of its prostheses and led to a voluntary suspension of Aeson implantations in Q421. Carmat recorded €2.3m in FY21 revenue from the sale of seven Aeson devices in Germany and Italy and three in the United States as part of an early feasibility study. After raising €40.5m in gross proceeds in April 2022, it reported a 30 June cash position of €47m, which provides a cash runway until March 2023.

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (fd) (c) P/E (x) P/CF (x)
2020A 0.0 N/A (38.7) (285.32) N/A N/A
2021A 2.2 N/A (61.9) (402.00) N/A N/A
2022E N/A N/A N/A N/A N/A N/A
2023E N/A N/A N/A N/A N/A N/A

Research

View All

More from our Healthcare team

Healthcare

Total Artificial Hearts

Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

sromanoff@edisongroup.com 020 3077 5700
Read latest

Thematics

View All

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free